Dectrekumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameDectrekumab
Drug Alias NameQAX-576
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-13 inhibitors
TargetsInterleukin-13
Therapy Area/IndicationsKeloidRhinitis, AllergicIdiopathic Pulmonary Fibrosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsKeloidRhinitis, AllergicIdiopathic Pulmonary Fibrosis +[6] 

Other Information

ATC CodeN/A
Related LinksN/A